University of Queensland, Brisbane, QLD, Australia.
Orbital Plastic and Lacrimal Clinic, Royal Victorian Eye and Ear Hospital, 32 Gisborne Street, East Melbourne, VIC, 3002, Australia.
Graefes Arch Clin Exp Ophthalmol. 2020 Sep;258(9):1999-2006. doi: 10.1007/s00417-020-04660-5. Epub 2020 Apr 6.
To investigate the efficacy of Permacol™, a decellularized porcine dermal-derived membrane, as a spacer in the management of lower eyelid retraction. The efficacy of sizing and insertion was investigated, as well as complications. The literature was also reviewed to compare this material with other porcine-derived grafts in use for the management of lower eyelid retraction.
This was a retrospective case series observing all patients who received lower eyelid Permacol implants by the two senior authors (AAM, TGH) for the management of lower eyelid retraction. Patient demographics, indications for surgery, graft size, degree of postoperative lid advancement, and complications were reviewed.
A total of 12 patients (16 eyelids) received Permacol implants for correction of lower eyelid retraction during the study period of 18 months (January 2015 to July 2017). Ten procedures were related to thyroid eye disease, 3 for reconstruction, 2 postcosmetic lower lid blepharoplasty, and one acquired anophthalmic socket. The average preoperative inferior scleral show (ISS) was 1.74 mm, and the average postoperative ISS was 0.82 mm. There was a mean lower eyelid elevation of 0.91 mm (p < 0.005, Wilcoxon signed rank test) and mean ratio of graft height:preoperative ISS was 3.8:1 over a median of 8 months follow-up.
Permacol is a safe and effective alternative to autologous tissues for use as a spacer in patients with lower eyelid retraction of varying etiologies. It does undergo some resorption with time, however this can be predicted and incorporated into surgical planning; we recommend an implant height:ISS ratio of 4:1.
研究 Permacol™(一种去细胞猪真皮衍生膜)作为下眼睑退缩治疗中隔离物的疗效。研究了其尺寸和插入的效果以及并发症。还对文献进行了回顾,以比较这种材料与其他用于治疗下眼睑退缩的猪源性移植物。
这是一项回顾性病例系列研究,观察了两位资深作者(AAM、TGH)为治疗下眼睑退缩而对所有接受下眼睑 Permacol 植入物的患者进行的研究。回顾了患者的人口统计学、手术适应证、移植物大小、术后眼睑提升程度和并发症。
在 18 个月(2015 年 1 月至 2017 年 7 月)的研究期间,共有 12 名患者(16 只眼)接受 Permacol 植入物治疗下眼睑退缩。10 例手术与甲状腺眼病有关,3 例用于重建,2 例为美容性下眼睑眼睑成形术,1 例为获得性眼窝。术前下巩膜暴露平均为 1.74mm,术后平均为 0.82mm。平均下眼睑抬高 0.91mm(p<0.005,Wilcoxon 符号秩检验),中位随访 8 个月时,移植物高度:术前 ISS 比值为 3.8:1。
Permacol 是一种安全有效的替代自体组织的材料,可作为各种病因下眼睑退缩患者的隔离物。它随时间会发生一些吸收,但这是可以预测的,并可纳入手术计划;我们建议植入物高度:ISS 比值为 4:1。